ERNA

Ernexa is, in its own words, "a preclinical-stage synthetic allogeneic iMSC therapy company" whose lead program ERNA-101 has yet to read out its first Phase 1 cohort. There is no commercial product and no durable revenue: the income statement shows a smattering of grant/service revenue (FY2024 $582K, FY2023 $68K, and no reported FY2025 revenue), while net losses have run in the tens of millions every year (-$44.5M FY2024, -$14.1M FY2025) against a -$246M accumulated deficit. This is a pure binary clinical-outcome bet, and the rubric's 'unknowable risk' test applies squarely.

The balance sheet is the immediate problem. FY2025 closed with just $1.88M cash against a -$7.02M annual operating cash burn — well under a year of runway on its own. Total equity is a thin $2.40M and liabilities/equity sits at 1.43x. The February 2026 placement raised ~$10.5M gross (net less than that after the $0.5M placement fee, $125K legal reimbursement, and agent shares), which buys perhaps another year but does not change the trajectory: this company must keep returning to the market to fund a multi-year preclinical-to-clinical journey, and the disclosed structure — 19M shares plus 19M Milestone Warrants (ERNAW) struck at $0.68 — makes further dilution the base case, not the risk case.